Optimistic
Last updated: 2026-04-17 18:42:00 ET
Pulse AI Brief
Updated Apr 17, 2026 5:10 PM ET
Eli Lilly's oral GLP-1 drug recorded 1,390 prescriptions in its first week on the market, signaling strong early adoption and physician confidence in the oral formulation. The pill format removes injection barriers and could expand the addressable market beyond current GLP-1 users who tolerate or prefer injectables.
Lilly's oral GLP-1 success validates the company's pipeline and supports premium valuation relative to Novo Nordisk, which dominates injectables. Strong early uptake could accelerate Lilly's market share gains in obesity and diabetes, driving revenue growth and justifying elevated stock multiples.
Oral GLP-1s are expanding the obesity treatment market by lowering friction for patients and providers. This could drive category growth beyond current estimates and intensify competition, but Lilly's early success positions it as a credible challenger to Novo's dominance.
Retail giant Express was publicly spilling customer information to the open web. The bug is now fixed after TechCrunch alerted Express, but the compan...
In a spilling of the court’s divisions in public, Sotomayor had criticized Kavanaugh over a dissenting ruling on ICE raidsSonia Sotomayor, a US supr...
'We've seen constraints in countries like Vietnam and Thailand on air travel, but this is also spilling over to Europe,' an ING analyst told CNBC.
Juliegrace Brufke, host of the "Sources Say Podcast" joins Major Garrett for a talk about the hottest gossip coming out of the nation's capital.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE